Research programme: substance P analogues - New Amsterdam Sciences

Drug Profile

Research programme: substance P analogues - New Amsterdam Sciences

Alternative Names: NAS-911; NAS-911B; NAS-911C; NAS-911DFU; NAS-911F; NAS-911PF; Neurokinin-1 receptor agonists - New Amsterdam Sciences

Latest Information Update: 12 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator New Amsterdam Sciences
  • Developer National Institutes of Health (USA); New Amsterdam Sciences
  • Class Peptides
  • Mechanism of Action Immunostimulants; Neurokinin 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute radiation syndrome; Cancer; Diabetic foot ulcer; Idiopathic pulmonary fibrosis; Influenza virus infections

Most Recent Events

  • 09 Aug 2014 New Amsterdam Sciences' substance P analogues programme is available for licensing as of 09 Aug 2014.
  • 06 Aug 2014 Preclinical trials in Acute radiation syndrome in USA (PO)
  • 06 Aug 2014 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top